A 1972 DeTomaso Pantera, formerly owned by Ford CEO Jim Farley, is being auctioned on Bring a Trailer. This specific vehicle has a unique history, including its delivery to Ford Aerospace in 1972 and a period as a museum display before Farley acquired it. The car's strong condition and Ford's historical ties to the Pantera nameplate are attracting significant collector interest and driving up its auction price.

A rare 1972 DeTomaso Pantera, formerly owned by Ford Motor Co. CEO Jim Farley, is currently up for auction on Bring a Trailer. The vehicle highlights

Cadence Design Systems (CDNS) CFO John M. Wall sold 21,500 shares of common stock at an average price of $309.45 per share on April 16, 2026, totaling over $6.65 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Wall directly holds 86,875 shares of the company's common stock.

General Motors has offered a substantial $40 million hiring package to Sterling Anderson, a former Tesla executive and co-founder of Aurora Innovation Inc., to lead its global product and serve as chief product officer. This significant investment reflects GM's strategy to accelerate its progress in self-driving vehicles, EVs, and software by attracting top talent from the tech industry. The compensation package for Anderson, which began with $16 million in 2025 and will continue into 2026 and 2027, is notably higher than the total compensation received by CEO Mary Barra and President Mark Reuss for the same period.

Truist has lowered its price target for Boston Scientific Corporation (BSX) to $90 from $92, while maintaining a Buy rating. This adjustment reflects multiple contraction for the MedTech group, though Truist anticipates the stock's valuation to rebound to at least 23-times its one-year forward earnings. RBC Capital also reduced its price target for BSX to $105 from $115, maintaining an Outperform rating, both updates coming ahead of fiscal Q1 results for MedTech companies.

CICC has initiated coverage of Pfizer Inc. (PFE) with an Outperform rating and a $33 price target. This follows Pfizer's announcement of positive topline results from its Phase 3 VALOR clinical trial for an investigational Lyme disease vaccine, showing over 70% efficacy with no safety concerns. The company plans to submit regulatory applications for the vaccine, highlighting its potential in an area with no currently available vaccines.

Ulta Beauty Inc (ULTA) shares surged 3.4% to $572.24, making it 3.0% overvalued according to its GF Value of $555.55. Despite this, the company boasts an impressive GF Score of 99/100, driven by perfect scores in Profitability and Growth. However, investors are cautioned by recent insider selling activity, with $0.2 million in shares sold over the last three months and no buying reported.

Arch Capital Group (ACGL) has increased its share repurchase authorization by $3 billion, signaling confidence in its financial health and commitment to shareholder returns. The company boasts a strong GF Score of 92/100 and an attractive P/E ratio of 8.39, suggesting potential undervaluation. However, recent insider selling of $7.3 million warrants investor attention.

Biogen Inc (BIIB) shares surged 3.4% to $183.34, leading to a "fairly valued" verdict from GF Value™ despite being 8.6% undervalued compared to the $200.50 estimate. The company's GF Score™ of 72/100 indicates solid potential, primarily driven by its perfect 10/10 Valuation score, though growth prospects are limited (2/10 G.F Rating). Insider selling activity of $0.7 million in the last three months suggests caution for potential investors.

Pharvaris N.V.'s Chief Medical Officer, Lu Peng, reported a routine tax-related share withholding event. On April 16, 2026, 226 common shares were disposed of at $28.78 per share to satisfy tax obligations from vested restricted stock units. After this transaction, Lu Peng directly holds 66,083 common shares.